Priestman 1996

Methods	RCT: enrolled: 533 evaluated: 352
Participants	Inclusion: 1. Symptomatic cerebral metastases confirmed on CT/radioisotope scans/biopsy 2. Histologic confirmation of primary 3. If no obvious primary, biopsy brain metastases 4. Presence of symptoms related to brain metastases 5. Stable dose of decadron 1 wk prior to randomization 6. 16 y.o. and over 7. WHO performance status zero to three; NFC < 4 (MRC) Exclusion: 1. Cytotoxic chemotherapy in prior four weeks
Interventions	1200 cGy/2 fr versus 3000 cGy/10 fr
Outcomes	1. Survival 2. Neurologic symptom response (3. Cause of death) (4. Morbidity)
Notes	QS = 3